Lakshmi Amaravadi

Head of Oncology Bioanalytical Strategy Team, Clinical Pharmacology & Safety Sciences AstraZeneca

Lakshmi Amaravadi, PhD, is Head of Oncology Bioanalytical Strategy at AstraZeneca, overseeing PK, PD, and immunogenicity strategies supporting preclinical and clinical programs across multiple modalities. She has more than 30 years of drug-development experience across oncology, neurology, autoimmune, metabolic, and rare diseases. During her career at Biogen, Sanofi, Shire, and Boston Pharma, she supported numerous successful INDs, BLAs, NDAs, and registrations. An active AAPS scientific-community leader and former board member, Lakshmi is passionate about innovative translational approaches and mentoring the next generation of scientists. She holds a Ph.D. in Cell, Molecular and Developmental Biology.

Seminars

Wednesday 10th March 2027
Expanding ADC Use Across Tumour Types & Patient Populations for Difficult to Treat Solid Tumours Including Pancreatic, Glioblastoma, and Sarcomas
2:15 pm
  • Developing stage-appropriate bioanalytical strategies for conventional and dual-payload ADCs
  • Using clinical case studies to inform ADC immunogenicity assessment across indications and development stages
  • Applying science- and risk-based approaches to dual-payload ADCs and combinations
Lakshmi Amaravadi